MP0712
Solid Tumors (DLL3-positive, e.g., SCLC)
PreclinicalLead Radio-DARPin program
Key Facts
Indication
Solid Tumors (DLL3-positive, e.g., SCLC)
Phase
Preclinical
Status
Lead Radio-DARPin program
Company
About Molecular Partners
Molecular Partners AG is a pioneer in the development of DARPin (Designed Ankyrin Repeat Protein) therapeutics, an entirely new class of custom-built protein drugs designed to overcome limitations of conventional biologics. The company leverages its proprietary platform to create multi-specific, logic-gated, and radio-conjugated drug candidates, primarily targeting cancers with high unmet need. Its strategy combines in-house R&D expertise with strategic partnerships to advance a diverse pipeline, including its lead programs MP0533 for AML and MP0712 for solid tumors.
View full company profile